AEON

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine.

Wall Street analysts forecast AEON stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AEON is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Aeon Biopharma Inc revenue for the last quarter amounts to -2.53M USD, decreased -37.00 % YoY.

Aeon Biopharma Inc. EPS for the last quarter amounts to -2596000.00 USD, decreased % YoY.

Aeon Biopharma Inc (AEON) has 5 emplpoyees as of December 16 2025.

Today AEON has the market capitalization of 10.08M USD.